TrialCancer chemotherapy and pharmacology2015

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.

Ying Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.